New and Future Focused Therapies for Thyroid Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 February 2025 | Viewed by 191

Special Issue Editors


E-Mail Website
Guest Editor
Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy
Interests: thyroid cancer; autoimmune thyroid diseases; thyroid irAE; Graves’ disease; thyroid eye disease; molecular basis of thyroid cancer; advanced thyroid cancer; tyrosine kinase inhibitors; medullary thyroid cancer; in vitro cell culture
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy
Interests: thyroid cancer; autoimmune thyroid diseases; thyroid irAE; Graves’ disease; thyroid eye disease; molecular basis of thyroid cancer; advanced thyroid cancer; tyrosine kinase inhibitors; medullary thyroid cancer; occupational health; public health, in vitro cell culture
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor

E-Mail
Guest Editor
Department of Surgery, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy
Interests: thyroid cancer; immunotherapy; new checkpoint inhibitors; tyrosine kinase inhibitors; PD-1 inhibitors; PD-L1 inhibitors

Special Issue Information

Dear Colleagues,

The incidence of thyroid cancer (TC) is increasing worldwide and new strategy treatments are needed. Treatments against TC are based on the subtypes of TC; differentiated TC usually has a good prognosis, unlike dedifferentiated TC of which the prognosis is not so promising, and require a more challenging approach. Among the approved therapies for TC, for aggressive radioiodine-resistant papillary or follicular TC, multi-targeted kinase inhibitors sorafenib, lenvatinib and cabozantinib have been approved. New compounds acting against specific mutations such as dabrafenib and trametinib have been recently approved for the treatment of BRAFV600E-mutated anaplastic TC.

Lately, new advancements in the molecular field are permitting to choose appropriate and patient-tailored therapy for the treatment of thyroid cancer. 

Prof. Dr. Alessandro Antonelli
Dr. Poupak Fallahi
Dr. Silvia Martina Ferrari
Dr. Giusy Elia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • aggressive differentiated thyroid carcinoma
  • anaplastic thyroid cancer
  • tyrosine kinase inhibitors
  • immunotherapy
  • personalized medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop